Investigation of the Efficacy and Safety of Xeligekimab (GR1501) in Patients with Moderate-to-Severe Plaque Psoriasis: A Multicenter, Randomized, Double-Blind Phase II Clinical trial.

Dermatol Ther (Heidelb) · 2025 · PMC12454832 · PMID 40517362

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Exploratory Endpoints Analysis Multiple-Dose Phase At weeks 4 and 12 post administration, IL-17A levels in peripheral blood were higher in the treatment groups compared with placebo, but the differences did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.